<DOC>
	<DOCNO>NCT00683618</DOCNO>
	<brief_summary>This trial compare efficacy , safety tolerability Rosuvastatin Atorvastatin assess change LDL-C patient hypercholesterolemia history coronary heart disease ( CHD ) risk equivalent , 10 year CHD risk le 10 % , follow 6-week treatment possible 6 week extension treatment .</brief_summary>
	<brief_title>Compare Efficacy Rosuvastatin Atorvastatin High Risk Patients With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Treated diagnosed hypercholesterolemia high risk hypercholesterolemia LDLC 3.36mmol/L 6.5 mmol/L treat statin 2.6mmol/L 4.14 mmol/L Fasting triglyceride less 4.52mmol/L History statin induce myopathy Unstable uncontrolled cardiovascular disease Familial dysbetalipoproteinemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HMG-CoA</keyword>
	<keyword>LDL-C</keyword>
	<keyword>CHD</keyword>
</DOC>